© Asian Pacific Society of Nephrology
Edited By: Peter G. Kerr
Impact Factor: 1.864
ISI Journal Citation Reports © Ranking: 2013: 38/77 (Urology & Nephrology)
Online ISSN: 1440-1797
Peter's Editorial Comments
"This study provides direct evidence that the PPAR-Y agonist, rosiglitazone, can protect against the loss of podocyte foor processes and down-regulation of podocyte slit diaphragm proteins in experimental focal and segmental glomerulosclerosis. Interestlingly, rosiglitazone reduced the degree of glomerulosclerosis and proteinuria, but did not prevent the loss of WT-1+ podocytes".